- Home
- ASAN vs XENE Comparison
ASAN vs XENE Comparison
Compare ASAN & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | XENE |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.4B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ASAN | XENE |
|---|---|---|
| Price | $12.99 | $41.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | $16.58 | ★ $53.91 |
| AVG Volume (30 Days) | ★ 3.3M | 808.7K |
| Earning Date | 12-02-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $773,570,000.00 | $7,500,000.00 |
| Revenue This Year | $11.38 | N/A |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.47 | N/A |
| 52 Week Low | $11.58 | $26.74 |
| 52 Week High | $24.50 | $46.60 |
Technical Indicators
Market Signals| Indicator | ASAN | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 38.05 |
| Support Level | $13.58 | $43.41 |
| Resistance Level | $14.05 | $46.36 |
| Average True Range (ATR) | 0.48 | 1.50 |
| MACD | -0.17 | -0.43 |
| Stochastic Oscillator | 13.17 | 9.92 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.